Shopping Cart
- Remove All
Your shopping cart is currently empty
Lorvotuzumab (Anti-NCAM1/CD56 Reference Antibody (lorvotuzumab)) is a humanized monoclonal antibody that binds to CD56 (NCAM1) and can be used to synthesize the antibody-drug conjugate Lorvotuzumab mertansine.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $313 | In Stock | |
| 5 mg | $793 | In Stock | |
| 10 mg | $1,290 | In Stock | |
| 25 mg | $1,890 | In Stock | |
| 50 mg | $2,580 | In Stock |
| Description | Lorvotuzumab (Anti-NCAM1/CD56 Reference Antibody (lorvotuzumab)) is a humanized monoclonal antibody that binds to CD56 (NCAM1) and can be used to synthesize the antibody-drug conjugate Lorvotuzumab mertansine. |
| In vivo | Lorvotuzumab mertansine (IMGN901) is an antibody-drug conjugate (ADC) that utilizes a disulfide linker to connect the potent anti-mitotic agent DM1 to the CD56-targeting antibody (Lorvotuzumab). Lorvotuzumab mertansine is effective against Wilms' tumor, rhabdomyosarcoma, and neuroblastoma. |
| Molecular Weight | 146.44 kDa |
| Cas No. | 339306-30-8 |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.